Insmed | INSM - Ebit

Aktienkurs
135.17
Täglich Wechseln
-8.66 -6.02%
Monatlich
-8.86%
Jährlich
93.96%
Q2 Prognose
132.28




Ebit Veränderung Datum
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
DBV Technologies USD -34.28M 6.83M 2025-09
Gilead Sciences USD 2.96B 551M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Novartis USD 4.06B 413M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12